Ixchelsis
Sandwich
About Ixchelsis
Ixchelsis Ltd is a clinical-stage biotechnology company developing an oxytocin receptor antagonist (IX-01) for the treatment of premature ejaculation (PE). IX-01 is a clinical stage asset that has the potential to be the best in class pharmacological approach for the treatment of PE. To date IX-01 has completed a Phase 1 single ascending dose study in healthy male volunteers and is currently being progressed through to clinical proof of concept (POC). Ixchelsis is funded by TVM Life Sciences Ventures VII and is lead by an excellent Management team with extensive experience in pharmaceutical R&D, particularly in the male sexual health therapeutic area.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $12.0M
- Last round: Series Unknown (Dec 2016)
- Website: ixchelsis.com
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/ixchelsis-162539 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.